Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 12, 2014, 173 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $57.29 to $21,893,760.00.

Highlighted Stocks Traded by Insiders:

Realpage (RP) - FREE Research Report

Steiner Jovanovic Janine, who is EVP Asset Optimization at Realpage, sold 3,329 shares at $21.20 on Nov. 12, 2014. Following this transaction, the EVP Asset Optimization owned 85,001 shares meaning that the stake was reduced by 3.77% with the 3,329-share transaction.

Chaney William P, who is EVP Enterprise Solutions at Realpage, sold 3,287 shares at $21.62 on Nov. 12, 2014. Following this transaction, the EVP Enterprise Solutions owned 83,838 shares meaning that the stake was reduced by 3.77% with the 3,287-share transaction.

The shares most recently traded at $22.49, up $0.87, or 3.87% since the insider transaction. Historical insider transactions for Realpage go as follows:

  • 4-Week # shares bought: 50,000
  • 4-Week # shares sold: 2,437
  • 12-Week # shares bought: 50,000
  • 12-Week # shares sold: 2,437
  • 24-Week # shares bought: 50,000
  • 24-Week # shares sold: 134,898

The average volume for Realpage has been 454,400 shares per day over the past 30 days. Realpage has a market cap of $1.8 billion and is part of the technology sector and computer software & services industry. Shares are down 3.94% year-to-date as of the close of trading on Wednesday.

RealPage, Inc. provides on demand software solutions for the rental housing industry in North America. Currently, there are 2 analysts who rate Realpage a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RP - FREE

TheStreet Quant Ratings

rates Realpage as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full

Realpage Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Realogy Holdings (RLGY) - FREE Research Report

Weaving David J, who is EVP and Chief Admin. Officer at Realogy Holdings, sold 7,818 shares at $42.54 on Nov. 12, 2014. Following this transaction, the EVP and Chief Admin. Officer owned 37,783 shares meaning that the stake was reduced by 17.14% with the 7,818-share transaction.

Zipf Bruce, who is Pres/CEO, NRT LLC at Realogy Holdings, sold 11,654 shares at $42.63 on Nov. 12, 2014. Following this transaction, the Pres/CEO, NRT LLC owned 42,669 shares meaning that the stake was reduced by 21.45% with the 11,654-share transaction.

The shares most recently traded at $43.05, up $0.42, or 0.98% since the insider transaction. Historical insider transactions for Realogy Holdings go as follows:

  • 4-Week # shares sold: 750
  • 12-Week # shares sold: 750
  • 24-Week # shares sold: 750

The average volume for Realogy Holdings has been 1.5 million shares per day over the past 30 days. Realogy Holdings has a market cap of $6.3 billion and is part of the financial sector and real estate industry. Shares are down 13.02% year-to-date as of the close of trading on Wednesday.

Realogy Holdings Corp. provides real estate and relocation services worldwide. The company has a P/E ratio of 14.4. Currently, there are 9 analysts who rate Realogy Holdings a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on RLGY - FREE

TheStreet Quant Ratings

rates Realogy Holdings as a

sell

. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, generally high debt management risk, poor profit margins, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full

Realogy Holdings Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Biogen Idec (BIIB) - FREE Research Report

Holtzman Steven H, who is EVP Corporate Development at Biogen Idec, sold 1,750 shares at $330.00 on Nov. 12, 2014. Following this transaction, the EVP Corporate Development owned 1,749 shares meaning that the stake was reduced by 50.01% with the 1,750-share transaction.

The shares most recently traded at $321.18, down $8.82, or 2.75% since the insider transaction. Historical insider transactions for Biogen Idec go as follows:

  • 4-Week # shares sold: 1,128
  • 12-Week # shares sold: 5,133
  • 24-Week # shares sold: 19,666

The average volume for Biogen Idec has been 1.3 million shares per day over the past 30 days. Biogen Idec has a market cap of $76.7 billion and is part of the health care sector and drugs industry. Shares are up 14.83% year-to-date as of the close of trading on Wednesday.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. The company has a P/E ratio of 30.7. Currently, there are 12 analysts who rate Biogen Idec a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BIIB - FREE

TheStreet Quant Ratings

rates Biogen Idec as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Biogen Idec Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null